Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer
2017; American Association for Cancer Research; Volume: 7; Issue: 7 Linguagem: Inglês
10.1158/2159-8290.cd-16-1174
ISSN2159-8290
AutoresMin Zou, Roxanne Toivanen, Antonina Mitrofanova, Nicolas Floc’h, Sheida Hayati, Yanping Sun, Clémentine Le Magnen, Daniel Chester, Elahe A. Mostaghel, Andrea Califano, Mark A. Rubin, Michael M. Shen, Cory Abate‐Shen,
Tópico(s)Hippo pathway signaling and YAP/TAZ
ResumoCurrent treatments for castration-resistant prostate cancer (CRPC) that target androgen receptor (AR) signaling improve patient survival, yet ultimately fail. Here, we provide novel insights into treatment response for the antiandrogen abiraterone by analyses of a genetically engineered mouse (GEM) model with combined inactivation of
Referência(s)